Google Cloud Launches AI Suites to Accelerate Drug Discovery and Development

Google Cloud unveiled two new AI research suites at Bio-IT World Conference to deepen its services for pharmaceutical and biotech. The Target and Lead Identification Suite and Multiomics Suite aim to accelerate drug discovery and precision medicine using advanced analytics.

The Target and Lead ID Suite helps predict protein structure, understand mutagenesis, and design novel therapeutics in silico. It combines AlphaFold2 for 3D protein modeling and Vertex AI, Google’s managed AI platform. This enables enhanced target identification and lead optimization.

Early adopters include Pfizer and neuroscience biotech Cerevel. Cerevel VP Claude Barberis says the Suite provides valuable insights to evaluate discovery efforts for neurodegenerative diseases like Parkinson’s. The company hopes the accelerated understanding can get urgently needed treatments to patients faster.

The Multiomics Suite analyzes diverse omics datasets for developing precision therapies. By integrating Google’s analytics and AI, it provides a scalable platform for multi-omics investigation.

Google Life Sciences head Shweta Maniar says the new solutions can transform drug discovery by fully leveraging AI’s potential. The company aims to create advanced tools for analyzing and engineering biology’s code for human benefit.

The suites demonstrate Google Cloud’s commitment to providing impactful capabilities for the life sciences industry. By combining predictive protein modeling, optimized lead design, and multi-omics analysis, Google hopes to enable fundamental advances in therapeutics discovery and development.

The Multiomics Suite enables streamlined analysis of massive genomic datasets for research. It is cloud agnostic, allowing flexible data ingestion and secure sharing. The Suite integrates tools like GATK and DeepVariant for secondary analysis, and enables drilling into disease genes with multimodal data for tertiary analysis.

This simplified environment empowers researchers to extract insights from vast troves of omics data. As Colossal Biosciences VP Alexander Titus explains, the Suite cut their costs 52% and analysis time 88% compared to open source tools. This dramatically improves computational efficiency for whole genome sequencing.

Colossal combines genetics and discovery to advance biology and medicine. The accelerated insights enabled by the Multiomics Suite will help them solve critical problems impacting life on Earth.

By leveraging Google’s analytics at scale while remaining cloud neutral, the Suite aims to remove major pain points in omics investigation. Researchers can now harness diverse genomic data more easily to unravel disease mechanisms and develop precision therapies.

The Multiomics Suite exemplifies how thoughtful AI design can empower scientists to gain knowledge from exponentially growing data. With streamlined capabilities across the discovery pipeline, Google Cloud hopes to drive breakthroughs in genomics-guided medicine.